{"url_path":"/sec/sgmo/8-k/2026-07-20/item-1-03","section_key":"item-1-03","section_title":"Item 1.03 Bankruptcy or Receivership.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-20","source_url":"https://www.sec.gov/Archives/edgar/data/1001233/0001193125-26-309012-index.html","accession_number":"0001193125-26-309012","cik":"0001001233","ticker":"SGMO","issuer_name":"SANGAMO THERAPEUTICS, INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1001233/0001193125-26-309012-index.html","primary_entity_key":"0001001233","primary_entity_name":"SANGAMO THERAPEUTICS, INC"},"word_count":405,"has_tables":true,"body_markdown":"Item 1.03 Bankruptcy or Receivership.\n\nAs previously disclosed, on June 23, 2026 (the “Petition Date”), Sangamo Therapeutics, Inc. (the “Company”) filed a voluntary petition (Case No. 26-10989) for relief under Chapter 11 of the Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware (such court, the “Court” and such case, the “Case”). On the Petition Date, the Company filed a motion (the “Bidding Procedures Motion”) (Docket No. 13) that sought approval of, among other things, certain auction and bidding procedures (the “Bidding Procedures”) in connection with a sale of all or substantially all of the Company’s assets and the approval designate stalking horse bidders. The Company continues to operate its business as a “debtor-in-possession” under the jurisdiction of the Court and in accordance with the applicable provisions of the Bankruptcy Code and orders of the Court.\n\nOn July 14, 2026, the Court entered an order (the “Bidding Procedures Order”) (Docket No. 122) granting the relief requested in the Bidding Procedures Motion. Pursuant to the Bidding Procedures Order, the Court approved, among other things, the Bidding Procedures, which provide for certain dates and deadlines in connection with the Company’s sale process, including the following:\n\nBid Deadline: Any party interested in submitting a bid for any of the Company’s assets must do so no later than August 4, 2026 at 5:00 p.m. (Eastern Time).\n\nAuction: If the Company receives more than one qualified bid (including a combination of bids that, when considered together, constitute a qualified bid) for the Company’s assets, the Company will conduct an auction for the assets on August 10, 2026 at 10:00 a.m. (Eastern Time).\n\nSale Hearing: The Sale Hearing will take place on August 20, 2026, at 10:00 a.m. (Eastern Time). At the Sale Hearing, the Company will seek the Court’s approval of the successful bids and any backup bids.\n\nThe Company’s objective in the Case is to maximize value for its stakeholders, which may be achieved through the sale of all or substantially all assets to the highest bidder or bidders, and/or through a reorganization with a chapter 11 plan sponsor. All information about the Case, including the full Bidding Procedures and access to Court documents, is available online at https://www.veritaglobal.net/SangamoTherapeutics, a website administered by Verita Global, a third-party bankruptcy claims and noticing agent. The information on this website is not incorporated by reference into, and does not constitute part of, this Current Report on Form 8-K."}